glp 1 brand names glp-1 receptor agonist Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Report What to Know About GLP-1s

Alpha-gal awareness on the rise Who should not take GLP-1s

After propensity score matching, there was no significant difference found for the risk of oral steroid use (aOR: 0.81, 95% CI: 0.481.36), intravenous steroid use (aOR: 0.69, 95% CI: 0.291.61), the need to initiate advanced therapy (aOR: 1.03, 95% CI: 0.412.60), or the risk of any-cause emergency department visits (aOR: 0.92 (0.521.61) at one year between the semaglutide-treated and non-semaglutide-treated IBD patients

Cabou C, Burcelin R

References 33 Cited by

Emerging data supports GLP-1s cardiovascular benefits, outweighing risks for most, but shared decision-making is key